Clinical Trials
6 trialsNCT06353360 2024-08-09
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 2 Unknown
NCT05540275 2023-10-06
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting
NCT04507217 2023-05-25
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
Sun Yat-sen University
Phase 2 Completed
NCT05502991 2022-09-27
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting
NCT05512351 2022-09-27
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
Henan Provincial People's Hospital
Phase 2 Recruiting
NCT05207904 2022-01-26
Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases
Sun Yat-sen University
Phase 2 Unknown